CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Deferiprone (L1) +2 moredrug
Likely dose
Deferiprone (L1) 100 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00349453
NCT00349453Phase 2Completed
CompareCT.gov

Retrospective and Prospective Multicenter Study Using Deferiprone (L1) Alone or in Combination With Desferrioxamine for the Treatment of Iron Overload in Transfusion-dependent Patients

Lipomed·interventional·Posted Jul 7, 2006·Updated Dec 12, 2011

In Brief

A Phase 2 clinical trial evaluating Deferiprone (L1) and Desferrioxamine for Hemochromatosis. Completed, enrolled 24 participants across 13 sites.

Detailed Summary

Systematical (retro- and prospective) investigation of the long-term safety (toxicity assessment according to CTCAE v3.0) and efficacy of deferiprone either given alone or in combination with desferrioxamine

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemochromatosis
CountriesSwitzerland
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 7, 2006
Enrollment StartMar 1, 2005
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 20.0 years ago

Interventions

Deferiprone (L1)drug

50-100 mg/kg body weight daily

Deferiprone (L1)drug

75 mg/kg body weight daily

Desferrioxaminedrug

35-50 mg/kg body weight on 2 or more days per week